尧唐生物日前宣布完成近五亿元人民币C轮融资，本轮融资由正心谷资本领投，上海国投先导等多家知名机构参与。依托其高通量编辑器挖掘和进化平台，以及非病毒载体LNP递送平台，尧唐生物致力于开发具有“一次给药、终身治愈”潜力的体内基因编辑药物。

YolTech Therapeutics recently announced the closing of its approximately USD 70 million Series C financing led by Loyal Valley Capital, with participation from Shanghai SSCI Leading Private Equity Fund and other renowned institutions. Built on HEPDONE™ Novel Editor Platform and non-viral LNP technologies, YolTech Therapeutics is advancing in vivo gene-editing medicines with the potential for a one-time treatment that provides lifelong benefit.

中伦律师事务所在本次交易中担任正心谷资本及上海国投先导的法律顾问，为本项目提供了全方位、全流程的法律服务。中伦项目组由合伙人刘天顺负责，成员包括律师郑雨宁等；合伙人赵靖亦为本项目提供了重要支持。

Zhong Lun acted as legal counsel to Loyal Valley Capital and Shanghai SSCI Leading Private Equity Fund in this transaction, providing comprehensive legal services throughout the entire process. The Zhong Lun team was led by partner Raphael Liu, and included associate Ruby Zheng, among others; partner Anthony Zhao also provided important support to this transaction.